127 related articles for article (PubMed ID: 17306936)
1. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
Jeremić B; Milićić B
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):426-32. PubMed ID: 17306936
[TBL] [Abstract][Full Text] [Related]
2. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
3. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Jeremić B; Milicić B; Acimović L; Milisavljević S
J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
[TBL] [Abstract][Full Text] [Related]
4. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
Jeremic B; Milicic B; Acimovic L; Milisavljevic S
J Clin Oncol; 2005 Feb; 23(6):1144-51. PubMed ID: 15718310
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
[TBL] [Abstract][Full Text] [Related]
6. Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
Am J Clin Oncol; 2004 Dec; 27(6):616-25. PubMed ID: 15577441
[TBL] [Abstract][Full Text] [Related]
7. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
Shibamoto Y; Jeremic B; Acimovic L; Milicic B; Nikolic N
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):295-300. PubMed ID: 11380214
[TBL] [Abstract][Full Text] [Related]
8. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
[TBL] [Abstract][Full Text] [Related]
10. [Radiochemotherapy of non-small-cell bronchial carcinoma. A report of experience].
Müller G; Kiricuta IC; Stiess J; Flentje M
Strahlenther Onkol; 1996 Aug; 172(8):446-54. PubMed ID: 8765348
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Schild SE; Bonner JA; Hillman S; Kozelsky TF; Vigliotti AP; Marks RS; Graham DL; Soori GS; Kugler JW; Tenglin RC; Wender DB; Adjei A
J Clin Oncol; 2007 Jul; 25(21):3124-9. PubMed ID: 17634491
[TBL] [Abstract][Full Text] [Related]
13. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
[TBL] [Abstract][Full Text] [Related]
14. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
[TBL] [Abstract][Full Text] [Related]
15. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
17. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
19. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
[TBL] [Abstract][Full Text] [Related]
20. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
